It is generally accepted in neurobiology that the integrity of the axon – the cable-like extensions that transmit information between neurons, muscles and sensory receptors – is wholly dependent on the health of the neuron cell body. This concept has been a guiding principle in the search for experimental therapeutics to treat neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. In this approach, protecting the cell body of the neuron should help to slow down or even stop the progression of neurodegeneration.

However, growing evidence from experiments in animals and observations in humans has shown that neurons, axons, and even the nerve terminals (which connect to the target muscle) respond differently to damage. This suggests that independent mechanisms of neurodegeneration may be at play in different regions of the neuron (Conforti et al., 2007, 2014). Therefore, treatments may need to target the entire neuron to achieve a significant therapeutic impact.

Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease that strikes without warning, typically in the prime of life. People with ALS become progressively weaker, which ruthlessly leads to disability, loss of independence and ultimately death. Therapeutic interventions are largely palliative, and dozens of clinical trials over the past three decades have failed to identify treatments that can slow down – never mind reverse or stop – the progression of this disease.

Promising results from pre-clinical experiments in animal models of the disease have not been successfully translated to humans, and the reasons for these failures are hotly debated. Of particular interest, largely because the findings are paradoxical, have been interventions in animal models of ALS that demonstrated near complete protection of the cell bodies of motor neurons, but failed to slow the progression of the disease. In these cases, protection of the motor neuron cell body by a variety of techniques did not prevent the loss of connectivity between the nerve terminals and the muscle (Gould et al., 2006; Parone et al., 2013; Klivenyi et al., 1999; Suzuki et al., 2007). This loss of connectivity is known as denervation.

Experimental studies in animal models of ALS have shown that the degenerative process of the disease starts at the nerve terminals and progresses proximally to the axon and eventually to the cell body of the neuron, a pattern described as ‘dying-back’ (Frey et al., 2000; Fischer et al., 2004). As with any ‘electrical’ system, the separation of the wire (the axon) from its target (the muscle) results in loss of function – or in the case of ALS, weakness and death. Now, in eLife, Steven Burden and colleagues from NYU Medical School and Columbia University – including Sarah Cantor as first author – report that protecting the connection between nerve and muscle could slow down the progress of the disease (Cantor et al., 2018).
The motor neuron connects to the muscles at the so-called neuromuscular junction, through which the neuron transmits signals to activate muscle contraction (Figure 1). Many proteins help to maintain this connection, including one called MuSK (Burden et al., 2013). During development, MuSK stimulates the attachment of the nerve terminal to the muscle. Later in life, MuSK is necessary to stabilize and maintain the neuromuscular junction, which ensures that signals can travel between the muscle, the nerve terminal and the motor axon. Indeed, damage or mutations to the MuSK gene are linked to other neuromuscular diseases.

Cantor et al. used a well-characterized mouse model of ALS to test if intervening with already damaged neuromuscular junctions could slow the progression of the disease. Their approach involved using an antibody that binds to and stimulates the activation of MuSK. The results showed that with the antibody, the neuromuscular junctions remained intact and functional for an extended period. In addition, the death of motor neurons was delayed, indicating that maintenance of muscle innervation plays a role in the support of the motor neuron cell body.

But even so, the animals only survived several days longer than normally. This might be due to the aggressive nature of the disease in this animal model, or possibly due to the lack of therapeutic targeting of the motor neuron cell bodies. Nevertheless, these findings suggest that protection of the neuromuscular junction could be a way to slow disease progression and keep neurons alive.

The pathogenesis and progression of ALS is an enigmatic and vexingly unresolved neurobiological problem. Genes and cellular pathways that represent possible upstream drivers of the disease are being discovered on a regular basis, and all of these may be specifically targeted. However, the approach of protecting neuromuscular junctions by targeting the underlying biology of maintenance is agnostic to these
upstream mechanisms and is also not specific to ALS. It could therefore help to preserve function in a variety of neuromuscular diseases where denervation is a major pathological feature.

Jonathan D Glass is in the Emory ALS Center, Emory University School of Medicine, Atlanta, United States

http://orcid.org/0000-0002-3295-4971

Competing interests: The author declares that no competing interests exist.

Published 19 March 2018

References

Burden SJ, Yumoto N, Zhang W. 2013. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harbor Perspectives in Biology 5: a009167. DOI: https://doi.org/10.1101/cshperspect.a009167, PMID: 23637281

Cantor S, Zhang W, Delestre N, Remédo L, Mentiis GZ, Burden SJ. 2018. Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody. eLife 7:e34375. DOI: https://doi.org/10.7554/eLife.34375, PMID: 29460776

Conforti L, Adalbert R, Coleman MP. 2007. Neuronal death: where does the end begin? Trends in Neurosciences 30:159–166. DOI: https://doi.org/10.1016/j.tins.2007.02.004, PMID: 17339056

Conforti L, Gilley J, Coleman MP. 2014. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nature Reviews Neuroscience 15:394–409. DOI: https://doi.org/10.1038/nrn3680, PMID: 24840802

Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD. 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Experimental Neurology 185:232–240. DOI: https://doi.org/10.1016/j.expneurol.2003.10.004, PMID: 14736504

Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. 2000. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. The Journal of Neuroscience 20:2534–2542. PMID: 10729333

Gould TW, Buss RR, Vinsant S, Prevett D, Sun W, Knudson CM, Milligan CE, Oppenheim RW. 2006. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. Journal of Neuroscience 26:8774–8786. DOI: https://doi.org/10.1523/JNEUROSCI.2315-06.2006, PMID: 16928866

Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Werner M, Kaddurah-Daouk R, Beal MF. 1999. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine 5:347–350. DOI: https://doi.org/10.1038/nrn6568, PMID: 10086395

Parone PA, Da Cruz S, Han JS, McAlonis-Downes M, Vetto AP, Lee SK, Tseng E, Cleveland DW. 2013. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. Journal of Neuroscience 33:4657–4671. DOI: https://doi.org/10.1523/JNEUROSCI.1119-12.2013, PMID: 23486940

Suzuki M, McHugh J, Tork C, Shelley B, Klein SM, Aebischer P, Svendsen CN. 2007. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2:e689. DOI: https://doi.org/10.1371/journal.pone.0000689, PMID: 17668067